home / stock / vcka / vcka news

VCKA News and Press, Vickers Vantage Corp. I From 05/16/22

Stock Information
Company Name: Vickers Vantage Corp. I
Stock Symbol: VCKA
Market: NASDAQ
Menu
VCKA VCKA Quote VCKA Short VCKA News VCKA Articles VCKA Message Board
Get VCKA Alerts

News, Short Squeeze, Breakout and More Instantly...
VCKA - Scilex Holding Company, a Sorrento Company, and Vickers Vantage Corp. I announced today the filing of a Registration Statement on Form S-4 with the Securities and Exchange Commission relating to the previously announced proposed business combination betwe

PALO ALTO, Calif. and NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”) and Vickers Vantage Corp. I (Nas...
VCKA - Scilex, a Sorrento Company, Highlights Safety Data From Phase 1 Trial of SP-104, a Proprietary Low Dose Naltrexone for Fibromyalgia

SP-104 is a novel, proprietary, fixed dose, delayed burst release of low dose naltrexone hydrochloride, 4.5 mg, for treatment of fibromyalgia (FM). There is a clear medical need for new, safe and effective treatments with the potential to improve care for the estimated 10 million FM p...

VCKA - Scilex, a Sorrento Company, Announces Pivotal Phase 3 SP-102 (SEMDEXA(TM)) Data Presentation At The American Society Of Interventional Pain (ASIPP) 2022 Annual Meeting

SP-102 (SEMDEXA TM ) is the first non-opioid novel injectable corticosteroid gel formulation product in development for the treatment of lumbar radicular pain, and it contains no preservatives, surfactants, solvents, or particulates. The study met its primary endpoint with a hig...

VCKA - Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., to Present SP-102 (SEMDEXA(TM)) Efficacy and Safety Data from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management at the 24th Annual Meeting of America

PALO ALTO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developin...
VCKA - Sorrento subsidiary Scilex expands distribution network to national, regional wholesalers

Scilex Holding Co., a subsidiary of Sorrento Therapeutics (NASDAQ:SRNE), is expanding its direct distribution network to national and regional wholesalers and pharmacies. Scilex said the move gives it better control over distribution of its lidocaine patch Ztildo and to launch future products...

VCKA - Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Expanding Its Direct Distribution Network to National And Regional Wholesalers And Pharmacies

PALO ALTO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developin...

VCKA - Dr. Henry Ji, Sorrento Therapeutics' Chairman and CEO and Scilex Holding Company's Executive Chairman, to Present at the B. Riley Securities' 2022 Virtual Neuro & Opthalmology Healthcare Conference (April 27-28, 2022)

SAN DIEGO and PALO ALTO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) today announced that Dr. Henry Ji, Chairman and CEO of Sorrento and Executive Chairman of Scilex Holding Company (“Scilex”), will participat...
VCKA - Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Strengthens Board of Directors with Appointment of Highly Accomplished Pharmaceutical and Biotechnology Executive, Laura Hamill

PALO ALTO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developin...

VCKA - Vickers Vantage I extends time to complete business combination

Vickers Vantage (VCKA +0.1%) has further extended the time it has to consummate an initial business combination by an additional three months. In connection with the extension, the Co.’s sponsors have deposited an aggregate of $1.04M into the trust account established in connectio...

VCKA - Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., announces continuous sales growth in ZTlido® with preliminary gross sales of approximately $8.1 million during the month of March 2022 and $18.4 million for 1Q2022

ZTlido 53% year-over-year preliminary unaudited gross sales in March 2022 Select payor accounts representing approximately 200 million of the over 300 million covered lives across the United States PALO ALTO, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (&...
Previous 10 Next 10